A sandwich-type ECL immunosensor based on signal amplification using a ZnO nanorods-L-cysteine-luminol nanocomposite for ultrasensitive detection of prostate specific antigen.
A sandwich-type ECL immunosensor based on signal amplification using a ZnO nanorods-L-cysteine-luminol nanocomposite for ultrasensitive detection of prostate specific antigen.
复制标题
DOI：
10.1016/j.aca.2020.02.056
复制
发表时间：
2020-05
影响因子：
6.2
通讯作者：
Yingcong Zhang;Ze Zhang;Shengzhong Rong;Hong-wei Yu;Hongmin Gao;Q. Sha;P. Ding;Hongzhi Pan;D. Chang
中科院分区：
文献类型：
--
作者：
Yingcong Zhang;Ze Zhang;Shengzhong Rong;Hong-wei Yu;Hongmin Gao;Q. Sha;P. Ding;Hongzhi Pan;D. Chang
基于ZnO纳米棒-半胱氨酸-鲁米诺纳米复合物和生物素-链霉亲和素体系，构建了一种用于检测前列腺特异性抗原（PSA）的超灵敏电化学发光（ECL）免疫传感器。生物素-链霉亲和素系统用作捕获探针以增加抗体的数量。ZnO纳米棒不仅作为纳米载体增加了鲁米诺分子和二抗的数量，而且通过促进H2 O2的分解，增强了鲁米诺-H2 O2体系的电化学发光信号，进一步增强了电化学发光强度。在优化条件下，该免疫传感器具有良好的分析性能，线性检测范围为0.03 pg mL− 1 ~ 30 ng mL− 1，检测限为0.01 pg mL−1（真实的样品的检测限为0.021 pg mL−1）。该方法具有良好的稳定性、重现性和选择性。此外，PSA测定结果在人血清样品中获得使用拟议的免疫传感器与使用商业化学发光免疫分析仪收集的数据是一致的。
An ultrasensitive sandwich-type electrochemiluminescence (ECL) immunosensor was developed for detection of prostate specific antigen (PSA) using an amplification strategy based on ZnO nanorods-l-cysteine-luminol nanocomposites and the biotin-streptavidin system. The biotin-streptavidin system served as a capture probe to increase the number of antibodies. ZnO nanorods not only acted as a nanocarrier that increased the number of luminol molecules and secondary antibodies, but also enhanced the ECL signal of luminol-H2O2system by promoting H2O2decomposition, which can further increase ECL intensity. Under optimized conditions, the proposed immunosensor demonstrated excellent analytical performance with a wide linear detection range of 0.03 pg mL−1to 30 ng mL−1and a detection limit of 0.01 pg mL−1(the detection limit in real samples was 0.021 pg mL−1). This method exhibited excellent stability, reproducibility, and selectivity. In addition, the results of PSA determinations in human serum samples obtained using the proposed immunosensor were consistent with data collected using the commercial chemiluminescence immunoassay analyzer.